Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 9/20 | 0.56 |
| ▸ | TNF | P01375 | 5/20 | 0.56 |
| ▸ | IL1B | P01584 | 4/20 | 0.56 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.46 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27098855 | 0.94 | CRBN (0.66) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL25454604 | 0.94 | CRBN (0.66) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL19612009 | 0.89 | CRBN (0.62) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL19612008 | 0.89 | CRBN (0.62) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL19611901 | 0.86 | CRBN (0.58) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL19611900 | 0.86 | CRBN (0.58) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL20496785 | 0.86 | CRBN (0.63) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL19629637 | 0.86 | CRBN (0.63) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL25565708 | 0.85 | CRBN (0.52) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL21946746 | 0.84 | CRBN (0.62) | CRBNIKZF3TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562917-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190276474-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-09-12 | — | — | US | disclosed |
| US-9938302-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170334932-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170333443-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2017-11-23 | — | — | US | disclosed |
| WO-2017201069-A1 | OXOINDOLINE DERIVATIVES AS PROTEIN FUNCTION MODULATORS | BIOTHERYX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562917-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | IKZF3, IKZF1, CKS1B | CRBN 176/4885IKZF3 1/4885TNF 6/4885 |
| US-20170333443-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | CRBN 176/4885IKZF3 1/4885TNF 6/4885 |
| US-20170334932-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | CRBN 176/4885IKZF3 1/4885TNF 6/4885 |
| US-20190276474-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | CRBN 176/4885IKZF3 1/4885TNF 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.